

ASX RELEASE

ASX Code: ESE

28 May 2020

eSense-Lab enters into Letter of Intent with SeaLaria Ltd

Life sciences company eSense-Lab Limited (**ASX:ESE**) ("**eSense**" or the "**Company**") is pleased to announce that it signed a Letter of Intent ("**LOI**") with SeaLaria Ltd ("**SeaLaria**"), a private Marine-Biotechnology company in Israel (<https://www.sealaria.co.il/>). The LOI is for a joint venture in developing new products based on the synergistic effect of eSense's terpene strains, and SeaLaria's unique gelatinised red algae.

The initial focus of the joint venture will be on healthcare and consumer anti-viral hand sanitisers. The infusion of terpenes to enhance the anti-viral potency and reduce the existing high alcohol content present in hand sanitisers and related products will be tested and produced.

eSense's CTO, Dr. Eyal Kalo, said the lab teams have been engaged to formulate the first experimental batch of a gel-based, alcohol free sanitiser. Preliminary results have been received and are currently being considered by the Company.

Additionally, eSense is developing an ointment to infuse combinations of SeaLaria's gelatinised algae along with eSense's best anti-inflammatory and anti-proliferative terpene blends. eSense plans to enter collaboration with hospital-based dermatology key opinion leaders to examine the therapeutic effects of these terpene/algae combinations on skin disorders.

Itzik Mizrahi, CEO of eSense, said "We have looked into possible cooperation with SeaLaria for some time, but the increased consumer demand for hand sanitisers has pushed both companies to prioritise the potential development of more effective products, to match consumer demand. I believe this joint venture will also produce other high efficiency products, leveraging both our companies' expertise."

The two companies have also initiated discussions to enter a collaboration process with relevant universities' virology lab or certified hospital virology lab, to run future testing of anti-viral synergistic effects.

Updated commercialisation strategy

Under the new leadership team eSense has been exploring a new commercialisation structure through joint venture agreements across multiple revenue-generating markets. In particular, the Company is researching innovative, evidence-based applications of terpenes for the medical, wellness, cosmetic, and nutritional markets.

Like the SeaLaria LOI, eSense intends to provide its proprietary terpenes technology to infuse the flavour and fragrance qualities and medicinal and well-being benefits into a range of products. The structure will leverage its partners' experience in marketing, sales and distribution in their specific markets.

This announcement has been authorised by the Board of Directors of eSense.

Ends



For further information, please contact:

Company Secretary

James Bahen

+61 8 6555 2950

info@esense-lab.com

Investor Enquiries

Gigi Penna

+61 404 147 568

info@esense-lab.com

About eSense-Lab | Registered office: Suite 6, 295 Rokeby Road, Subiaco Western Australia, Australia 6008

eSense-Lab Ltd (ASX:ESE) is a life sciences company creating virtual plant-based products for medicinal and recreational consumption. Headquartered in Israel, eSense-Lab combines genetics, mRNA expression, phytochemical characterisation and unique formulations to generate comprehensive models of rare or high value plants. With multi-disciplinary research and development expertise, eSense has game-changing techniques and unique reverse-engineering capabilities, placing it at forefront of the growing international terpene market. eSense has created virtual cannabis, with all the characteristics of the real plant, without the psychoactive and heavily regulated cannabinoid compound, for mass consumer consumption.

To learn more, please visit www.esense-lab.com.

